This website is for UK healthcare professionals only and contains promotional content.

Report an adverse event here
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

Oncology

Adverse Events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk/. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

Abstral® (fentanyl citrate) Sublingual Tablet

Abstral® is indicated for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.1

  • PRESCRIBING INFORMATION

    Direction on prescribing Abstral®.

  • RISk MATERIAL

    Educational risk minimisation materials to help reduce the risk associated with using this medicine.

  • Responsible Usage
    Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain. Please note not all medicines containing opioids are authorised for all types of pain indication. Refer to the summary of product characteristics before prescribing. For advice on the responsible use of opioids, including those indicated for other types of pain, please click here.

PecFent® (fentanyl citrate) Nasal Spray

PecFent® is indicated for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.2

  • PRESCRIBING INFORMATION

    Direction on prescribing PecFent®.

  • RISK MATERIALS

    Educational risk minimisation materials to help reduce the risk associated with using this medicine.

  • Responsible Usage
    Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain. Please note not all medicines containing opioids are authorised for all types of pain indication. Refer to the summary of product characteristics before prescribing. For advice on the responsible use of opioids, including those indicated for other types of pain, please click here.

SANCUSO® (granisetron) Transdermal Patch

SANCUSO® transdermal patch is indicated in adults for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive days, where oral anti-emetic administration is complicated by factors making swallowing difficult.3

Average:

  • References

    1. Abstral® Summary of Product Characteristics.

    2. PecFent® Summary of Product Characteristics.

    3. SANCUSO® 3.1 mg/24 hours transdermal patch Summary of Product Characteristics.

    M-GRM-HQ-11-23-0012 June 2025

This website is for healthcare professionals only.

If you are a registered healthcare professional outside the UK please visit the Grünenthal Meds Website

M-GRM-HQ-11-24-0006 May 2025